Mizawa Megumi, Makino Teruhiko, Hikiami Hiroaki, Shimada Yutaka, Shimizu Tadamichi
Department of Dermatology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Sugitani, Toyama 2630, Japan.
ISRN Dermatol. 2012;2012:158598. doi: 10.5402/2012/158598. Epub 2012 Nov 14.
Atopic dermatitis (AD) is a common inflammatory skin disease with recurring episodes of itching and a chronic relapsing course. Keishibukuryogan (KBG) is a traditional herbal medicine, composed of five kinds of medical plants and has been administered to patients with blood stagnation in Japan. This study investigated the effect of KBG on the disease activity in AD (n = 45) patients. AD patients were administered KBG for 4 to 6 weeks in addition to their prescribed medications. The results showed that the SCORAD index and VAS score were significantly decreased after the administration of KBG (P < 0.01). KBG also decreased the serum LDH level significantly (P < 0.01). The global assessment of the clinical response in SCORAD index showed that 88.5% of the patients with moderate improvement to excellent response (n = 26) had a high lichenification score (lichenification score ≥2 in SCORAD). On the other hand, only 42.1% of the patients with no improvement to mild improvement (n = 19) had a high lichenification score. Furthermore, long-term administration of KBG for 9-67 weeks showed a marked improvement in patients with a high lichenification score. Therefore, KBG was found to be effective against AD, particularly in cases presenting with lichenified lesions.
特应性皮炎（AD）是一种常见的炎症性皮肤病，伴有反复瘙痒发作和慢性复发病程。桂枝茯苓丸（KBG）是一种传统草药，由五种药用植物组成，在日本已用于治疗血瘀患者。本研究调查了KBG对AD患者（n = 45）疾病活动的影响。AD患者在服用规定药物的基础上，加服KBG 4至6周。结果显示，服用KBG后，SCORAD指数和VAS评分显著降低（P < 0.01）。KBG还显著降低了血清LDH水平（P < 0.01）。SCORAD指数中临床反应的整体评估显示，88.5%的中度改善至显著改善患者（n = 26）有较高的苔藓化评分（SCORAD中苔藓化评分≥2）。另一方面，在无改善至轻度改善的患者（n = 19）中，只有42.1%有较高的苔藓化评分。此外，对苔藓化评分高的患者长期服用KBG 9至67周显示出明显改善。因此，发现KBG对AD有效，尤其是在出现苔藓化病变的病例中。
